secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001787306-25-000004
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis reports Q4 product revenue ~$63M (+366% YoY); FY2024 ~$160M (+449% YoY)
-------------------------------------------------------------------------------

- Preliminary Q4 2024 product revenue ~$63M, up ~366% vs Q4 2023 and ~41% vs Q3 2024.
- Full-year 2024 product revenue ~$160M, up ~449% compared to 2023, driven by ZORYVE demand.
- Cash and marketable securities ~$229M as of Dec 31, 2024; total liquidity ~$329M after $100M debt repayment and re-draw option.
- Gross-to-net similar to prior quarter; robust unit growth across portfolio.
- Company to report complete Q4/FY2024 results and host conference call on Feb 25, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730625000004/0001787306-25-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730625000004/arqt-20250112.htm
  HTML page:      https://secwatch.observer/filing/0001787306-25-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer